• About us
• Contact

Advertisement

Organisation › Details

Remix Therapeutics Inc.

Remix Therapeutics is a clinical stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster™ technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix’s innovative therapeutic approach has the potential to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. *

 

	Start	2020-12-08 existent
	Industry	RNA processing targeted therapeutics
	Industry 2	RNA processing reprogramming technology
	Person	Smith, Peter (Pete) (Remix Therapeutics 202012 CSO + Co-Founder)
	Person 2	Bitterman, Kevin (Atlas Venture 2017– Partner before Polaris Partners since 2004)
	Region	Watertown, MA
	Country	United States (USA)
	Street	100 Forge Road Suite 400
	City	02472 Watertown, MA
	Tel	+1-781-827-0901
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«: Remix Therapeutics, Inc.. (1/3/24). "Press Release: Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing". Watertown, MA.
		Record changed: 2024-01-03

Advertisement

More documents for Remix Therapeutics Inc.

• [1] Remix Therapeutics, Inc.. (1/3/24). "Press Release: Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing". Watertown, MA....
• [2] Remix Therapeutics, Inc.. (1/3/24). "Press Release: Remix Therapeutics Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease". Cambridge, MA....
• [3] Remix Therapeutics, Inc.. (12/21/23). "Press Release: Remix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference". Watertown, MA....
• [4] CRISPR Therapeutics AG. (12/19/22). "Press Release: CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development". Zug & Boston, MA....
• [5] Remix Therapeutics, Inc.. (12/8/20). "Press Release: Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.